Back
Amylyx Pharmaceuticals Quote, Financials, Valuation and Earnings
Sell
24
AMLX
Amylyx Pharmaceuticals
Last Price:
1.84
Seasonality Move:
87.32%
7 Day Trial
ALL ACCESS PASS
$
7
Amylyx Pharmaceuticals Price Quote
$1.84
+0.01 (+0.55%)
(Updated: May 18, 2024 at 5:37 AM ET)
Amylyx Pharmaceuticals Key Stats
Sell
24
Amylyx Pharmaceuticals (AMLX)
is a Sell
Day range:
$1.81 - $1.87
52-week range:
$1.70 - $27.98
Dividend yield:
0%
P/E ratio:
2.61
P/S ratio:
0.32
P/B ratio:
0.38%
Volume:
1.2M
Avg. volume:
2.1M
1-year change:
-93.41%
Market cap:
$124.5M
Revenue:
$380.8M
EPS:
$-1.07
How Much Does Amylyx Pharmaceuticals Make?
-
How Much Are Amylyx Pharmaceuticals's Sales Annually?
AMLX Revenues are $380.8M -
How Much Profit Does Amylyx Pharmaceuticals's Make A Year?
AMLX net income is $49.3M
Is Amylyx Pharmaceuticals Growing As A Company?
-
What Is Amylyx Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.24% -
What Is Amylyx Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Amylyx Pharmaceuticals Stock Price Performance
-
Did Amylyx Pharmaceuticals Stock Go Up Last Month?
Amylyx Pharmaceuticals share price went down by -8.5% last month -
Did AMLX's Share Price Rise Over The Last Year?
AMLX share price fell by -93.41% over the past 1 year
What Is Amylyx Pharmaceuticals 52-Week High & Low?
-
What Is Amylyx Pharmaceuticals’s 52-Week High Share Price?
Amylyx Pharmaceuticals has traded as high as $27.98 over the past 52 weeks -
What Is Amylyx Pharmaceuticals’s 52-Week Low Share Price?
Amylyx Pharmaceuticals has traded as low as $1.70 over the past 52 weeks
Amylyx Pharmaceuticals Price To Free Cash Flow
-
Is Amylyx Pharmaceuticals Stock Overvalued?
Amylyx Pharmaceuticals is trading at a price to free cash flow ratio of 8.21 -
Is Amylyx Pharmaceuticals Stock Undervalued?
Amylyx Pharmaceuticals EV to Free Cash Flow ratio is -16.11 -
What Is Amylyx Pharmaceuticals’s Price Earnings Growth Ratio?
AMLX PEG ratio is 0.00 -
Is Amylyx Pharmaceuticals Trading At A Premium To Earnings?
Amylyx Pharmaceuticals EV to EBIT ratio is 0.00
Is It Risky To Buy Amylyx Pharmaceuticals?
-
How Much Debt Does Amylyx Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Amylyx Pharmaceuticals Have?
Cash and short term investments quarterly total is $373.3M -
What Is Amylyx Pharmaceuticals’s Book Value Per Share?
Book value per share is 4.77
Is Amylyx Pharmaceuticals Cash Flow Positive?
-
What Is AMLX Cash Flow From Operations?
Cash flow from operations (TTM) is $16.5M -
What Is Amylyx Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $2.6M -
What Is Amylyx Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is $36.9M
Amylyx Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
AMLX return on invested capital is -18.56% -
What Is Amylyx Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -15.71% -
What Is AMLX Return On Equity?
ROE is a measure of profitability and is -18.56%
Amylyx Pharmaceuticals Earnings Date & Stock Price
-
What Is Amylyx Pharmaceuticals's Stock Price Today?
A single share of AMLX can be purchased today for 1.83 -
What Is Amylyx Pharmaceuticals’s Stock Symbol?
Amylyx Pharmaceuticals trades on the nasdaq under the ticker symbol: AMLX -
When Is Amylyx Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Amylyx Pharmaceuticals is scheduled on August 9, 2024 -
When Is AMLX's next ex-dividend date?
Amylyx Pharmaceuticals's next ex-dividend date is May 18, 2024 -
How To Buy Amylyx Pharmaceuticals Stock?
You can buy Amylyx Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Amylyx Pharmaceuticals Competitors
-
Who Are Amylyx Pharmaceuticals's Competitors?
Below is a list of companies who compete with Amylyx Pharmaceuticals or are related in some way:
Amylyx Pharmaceuticals Dividend Yield
Data Unavailable
Amylyx Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -1946.5% |
| Revenue: | 24.1% | -9.87% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 6 |
| Sell Recommendations: | 0 |
| Price Target: | 4.08 |
| Upside from Last Price: | 123.13% |